FDA advisory committee votes down approval of Boehringer and Lilly’s drug for type 1 diabetes
November 14, 2019Sales and Marketing Boehringer Ingelheim, Eli Lilly, empagliflozin, jardiance, pharma
Boehringer Ingelheim and Eli Lilly’s have been dealt a blow from the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC), …
Myeloma UK reveals new Director of Research appointment
November 14, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Myleoma UK, appointment, multiple myeloma, pharma
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, who in her new role …
NICE greenlights Consilient Health’s Elmiron for bladder pain syndrome
November 14, 2019Sales and Marketing NICE, consilient health, elmiron, pharma
NICE has chosen to recommend Consilient Health’s Elmiron (pentosan polysulfate sodium) for the treatment of bladder pain syndrome (BPS), it …
MSD’s proposed sale of French manufacturing plant puts over 200 jobs in jeopardy
November 14, 2019Manufacturing and Production France, MSD, pharma
MSD has announced its plans to put its Centre de Mirabel production facility in Riom, France up for sale – …
Wearable tech market set to double to $54 billion by 2023, report says
November 13, 2019Research and Development, Sales and Marketing pahrma, wearble technology
A new report from GlobalData has revealed that the market for wearable technology in healthcare is expected to more than …
Abbott CEO to step down after 21 years
November 13, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbott, appointment
After more than two decades at the head of the company, it has emerged that Miles D White (pictured, right) …
Vertex’s cystic fibrosis portfolio to be made available across Northern Ireland and Wales
November 13, 2019Research and Development, Sales and Marketing Kalydeco, NHS, Orkambi, Symkevi, Vertex, pharma
After drawn out negotiations and much discontent among cystic fibrosis (CF) patients and their advocates, Vertex has announced that a …
Mylan and Upjohn merger will create a new entity: Viatris
November 13, 2019Manufacturing and Production, Research and Development, Sales and Marketing Mylan, Pfizer, Upjohn, Viatris, pharma
The name for the new company emerging out of the merger between Pharma firm Mylan and Pfizer division Upjohn has …
GSK’s Nucala meets Phase 3 goal in reducing hypereosinophilic syndrome flare-ups
November 13, 2019Research and Development GSK, Nucala, pharma
GlaxoSmithKline has unveiled new Phase 3 data for its IL-5 inhibitor Nucala (mepolizumab), revealing that the therapy met its primary …
Pfizer’s tofacitinib hits main goal in Phase 3 juvenile idiopathic arthritis study
November 12, 2019Manufacturing and Production, Research and Development Pfizer, pharma, tofacitinib
Pfizer has lifted the lid on new Phase 3 data exploring the efficacy of tofacitinib in the treatment of juvenile …
Scottish Medicines Consortium recommends Eisai’s Kisplyx for advanced kidney cancer
November 12, 2019Manufacturing and Production, Sales and Marketing Eisai, Kisplyx, NHS, Sotland, pharma
Eisai’s Kisplyx (lenvatinib) has secured recommendation from the Scottish Medicines Consortium, it has been revealed, meaning that patients on the …
MSD secures EU approval for its Zaire Ebola vaccine Ervebo
November 12, 2019Manufacturing and Production, Sales and Marketing Ebola, Ervebo, MSD, pharma
MSD has scored approval from the European Commission for Ervebo, the company’s Zaire Ebola vaccine, for the prevention of Ebola …
Novartis’ Kisqali approved for NHS Scotland in most common advanced breast cancer
November 12, 2019Manufacturing and Production, Sales and Marketing Cancer, Kisqali, NHS, Novartis, Scotland, breast cancer, pharma
NHS patients in Scotland will soon be able to access Novartis’ CDK4/6 inhibitor Kisqali (ribociclib) after the Scottish Medicines Consortium …
Lonza CEO to step down in 2020
November 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Lonza, appointment
It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to step down from the role …
Working Life Interview: Alison Muir, Oncology Product Strategy Director at Roche
November 11, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Roche, Working Life, feature, pharma
You studied biology at Liverpool John Moores University before heading straight to GSK in 1990 as a Sales Representative; was …
NHS to utilise first-ever cannabis-based therapies following NICE recommendation of two GW Pharma drugs
November 11, 2019Sales and Marketing Epidyolex, GW Pharma, NHS, Sativex, pharma
The NHS is authorised to use its first two cannabis-based medicines for routine use after NICE saw fit to recommend …
Roche’s risdiplam hits main goal in spinal muscular atrophy type 2 or 3
November 11, 2019Research and Development, Sales and Marketing Roche, pharma, risdiplam, spinal muscular atrophy
Roche has lifted the curtain on new data which shows that its investigational survival motor neuron-2 (SMN2) splicing modifier risdiplam …
Novartis reveals strong Phase 2b data for tropifexor in non-alcoholic steatohepatitis
November 11, 2019Research and Development, Sales and Marketing Novartis, nash, non-alcoholic steatohepatitis, pharma
The latest findings have been revealed from the final stage of Novartis’ Phase 2b evaluation of its non-bile acid FXR …
AnaptysBio’s etokimab fails in moderate-to-severe atopic dermatitis
November 11, 2019Sales and Marketing AnaptysBio; atopic dermatitis, pharma
AnaptysBio has announced disappointing new Phase 2b data for its anti-IL-33 candidate etokimab in the treatment of moderate-to-severe atopic dermatitis. …
Celgene and Acceleron’s Reblozyl secures FDA approval for anaemia in beta thalassaemia
November 11, 2019Sales and Marketing Acceleron, Celgene, Reblozyl, beta thalassaemia, pharma
The FDA has moved to authorise Celgene and Acceleron Pharma’s Reblozyl (luspatercept-aamt) in the treatment of anaemia associated with the …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
